Clinical trial
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
NCT03452527 is registered in ClinicalTrials.gov with Iconic Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
- Lead sponsor
- Iconic Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- March 26, 2018
- Completion date
- April 25, 2019
- Enrollment
- 15 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.